DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Follow-Up Questions
Quel est le ratio P/E de Dbv Technologies SA (DBVT) ?
Le ratio P/E de Dbv Technologies SA est de N/A
Qui est le CEO de Dbv Technologies SA ?
Mr. Daniel Tasse est le Chief Executive Officer de Dbv Technologies SA, il a rejoint l'entreprise depuis 2018.
Quelle est la performance du prix de l'action DBVT ?
Le prix actuel de DBVT est de 9.6, il a increased de 0.13% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Dbv Technologies SA ?
Dbv Technologies SA appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Dbv Technologies SA ?
La capitalisation boursière actuelle de Dbv Technologies SA est de $262.6
Est-ce que Dbv Technologies SA est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour Dbv Technologies SA, y compris 3 achat fort, 3 achat, 1 maintien, 1 vente et 3 vente forte
